Impurity Reference Standard Selection in Finerenone Generic Filings: Identification and Control of the R-Configuration Enantiomer and Degradation Impurities
Finerenone (trade name Kerendia®)is a non-steroidal mineralocorticoid receptor antagonist (MRA) developed by Bayer, approved in China in 2022 for adult patients with type 2 diabetes-related chronic kidney disease (DKD). According to Bayer's 2024 annual report, Kerendia's full-year sales were approximately €463 million (about USD 540 million), up more than 71% year-on-year, with both the US and Chinese markets being major sources of growth.
Finerenone
CAS No.: 1050477-31-0
The rapidly expanding market has attracted a large number of generic drug companies: more than 30 companies, including Huapont Pharmaceutical, North China Pharmaceutical, and Conba Pharmaceutical, have already submitted Class 4 generic marketing applications for finerenone tablets to the CDE, among which Hunan Mingrui Pharmaceutical has taken the lead in obtaining approval for the domestic first generic; however, because the originator's compound patent does not expire until 2028, the launch of the first generic must still await patent expiration or a successful patent challenge.
In the fierce generic competition landscape, the quality of impurity research directly determines whether the filing documents can pass CDE technical review. The structural characteristics of finerenone determine that its impurity profile has two core concerns: chiral enantiomer impurities and multi-pathway degradation products. Both require corresponding reference standards to complete the establishment and validation of analytical methods compliant with ICH/ChP requirements.
1. The Chiral Structure of Finerenone and the Source of the R-Enantiomer
Finerenone contains one chiral center, located at the C4 position of the 1,4-dihydronaphthyridine ring. The active ingredient is the (4S) configuration, with the chemical name (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide, molecular formula C₂₁H₂₂N₄O₃, CAS number 1050477-31-0. Its enantiomer, the (4R) configuration (CAS 1050477-30-9), namely R-finerenone, is pharmacologically inactive toward the mineralocorticoid receptor.
The formation of the R-enantiomer is directly related to the synthetic route. According to the originator process paper by Lerchen et al. published in Angewandte Chemie International Edition (2020, PMC7839499), the early industrial synthesis of finerenone was a racemate route — first synthesizing the (4R,4S) racemate (CAS 1050477-27-4), then resolving the active S-enantiomer by chiral chromatography; the unwanted R-enantiomer could be converted back to the racemate through two steps for recycling, but this process is time-consuming and costly, and the contradiction is especially prominent when kilogram-scale production is required at the Phase III clinical trial stage. For this reason, the paper also reported the enantioselective total synthesis of (−)-finerenone through a chiral phosphoric acid-catalyzed asymmetric transfer hydrogenation route.
Regardless of the synthetic route used, as long as there are deviations in process control or incomplete chiral resolution, the R-enantiomer may enter the final product as a trace residue, becoming a specified known impurity that must be addressed in generic filings.
Related reference standard configuration recommendations:
2. Control Requirements for the R-Enantiomer: ICH Q6A Decision Tree 5
Decision Tree 5 in ICH Q6A clearly stipulates that, for a chiral API developed as a single enantiomer, the other enantiomer must be controlled in the same way as other impurities; the specification should include an enantioselective assay method, which may be a chiral assay method or a combination of a non-chiral assay with enantiomer impurity control. China has fully adopted ICH Q6A, and these requirements are equally applicable in CDE technical review.
ICH Q11 further points out that enantiomer impurity control can also be achieved by setting limits on starting materials and intermediates, but the filing documents must provide data demonstrating the stability of the chiral center under the proposed manufacturing conditions.
In practical method establishment, Al-Farhan et al. published in Chirality (2025, DOI: 10.1002/chir.70052) a simultaneous chiral HPLC method for finerenone and its 4R enantiomer developed using the AQbD framework: a CHIRALPAK AD-H column, an isocratic mobile phase of n-hexane:ethanol (62:38, v/v), baseline separation within 10 minutes (Rs = 3.5), and a limit of quantitation of 0.40 μg/mL for the 4R enantiomer. The method also defined the method operable design region (MODR) that ensures consistent performance.
The establishment and validation of this method presuppose obtaining a (4R)-finerenone reference standard with clear traceability (C4X-28809, CAS 1050477-30-9). Racemic finerenone (C4X-28801, CAS 1050477-27-4) is commonly used for system suitability verification of the chiral method — injecting an equal mixture of the S-form and R-form into the column to confirm that the resolution meets the requirement before sample testing.
3. Process Impurity Profile: The Synthetic Route Determines the Reference Standard List
The synthesis of finerenone involves multiple steps, and the main process impurities come from incomplete conversion of key intermediates, side reactions, or inadequate work-up. The following are the known process impurities commonly seen in filings:
Impurities closely related to the naphthyridine core skeleton:
Among them, impurity 12 (C₂₁H₂₀N₄O₃) differs from the finerenone parent drug (C₂₁H₂₂N₄O₃) by 2 hydrogen atoms, making it a dehydrogenation-type process impurity and a co-elution risk point that must be addressed in chromatographic method development. The CAS numbers of impurities 13 and 47 both fall within the Bayer original patent numbering range (1050477-xx-x), indicating that they were already identified and characterized during the originator's process development stage.
4. Degradation Impurities:
Degradation Behavior under Five Stress Conditions and Reference Standard Needs
Degradation products generated in forced degradation studies also need to be addressed and controlled in the related substances method.
According to a stability-indicating method study by Marie et al. published in Scientific Reports (2025, Article 20229, DOI: 10.1038/s41598-025-07166-4), finerenone was investigated under the stress conditions recommended by ICH Q1A(R2), including acid hydrolysis, base hydrolysis, oxidation, photolysis, and thermal degradation, with base degradation being the most pronounced.
Base degradation (most significant)
Under alkaline conditions, the recovery of finerenone decreased by approximately 28.35%, and three new degradation peaks appeared in the chromatogram. Analysis of its molecular structure suggests that alkaline conditions may promote hydrolysis of the amide group to form the corresponding degradation products, but the specific structures still require further confirmation by means such as LC-MS.
Acid degradation
Under acidic conditions, the recovery decreased by approximately 7.5%, with two degradation peaks appearing, a degradation extent significantly lower than base degradation, suggesting that finerenone has relatively good stability in acidic environments.
Oxidative degradation
Oxidative degradation can be observed under hydrogen peroxide stress conditions. Based on structural characteristics, the methoxy-substituted aromatic ring and nitrogen-containing heterocyclic sites may be potential oxidation reaction sites.
Photodegradation
Although the finerenone molecule contains an aromatic conjugated structure and photochemical degradation is theoretically possible, literature studies showed no significant degradation under the investigated light exposure conditions, suggesting good photostability.
Thermal degradation
Small amounts of thermal degradation products can be produced under solid-state thermal treatment, but the overall degradation extent is relatively mild.
For the major degradation peaks identified in forced degradation studies, if they persist in long-term stability studies or across multiple batches and exceed the identification threshold specified in ICH Q3A(R2), structural identification is required and an appropriate quality control strategy must be established. Since the daily dose of finerenone is only 10–20 mg, far below 2 g/day, the organic impurity identification threshold is typically 0.10%. For important degradation impurities that need to be controlled, companies usually need to establish a reliable quantification method, which may use the external standard method with impurity reference standards or the main-component self-reference method validated by response factors (RRF).
Conclusion
As one of the most fiercely competitive generic products in China, finerenone has filings from more than 30 companies under CDE review. The depth of impurity research and the standardization of reference standard configuration will create clear differentiation during the review process. The (4R)-enantiomer as the chiral source impurity (C4X-28809) and the base degradation product as the main degradation pathway are the two priority concerns in establishing the impurity profile. In reference standard selection, prioritizing certified reference standards with ISO 17034 traceability can reduce the risk of filing deficiency letters and accelerate the review process.
For more details on finerenone products, please contact CATO